

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Tsay, Marsha M.
Group Art Unit: 1656

In re PATENT APPLICATION of
Applicants: HOSOKAWA ET AL.

Serial No. : 10/599,050

Filed : June 29, 2007

For : THROMBIN DERIVATIVES AND PHARMACEUTICAL
COMPOSITION CONTAINING THE SAME

)
)
)
) AMENDMENT

No fee is believed to be due. However, the Commissioner is authorized to charge any fees required in connection with the filing of this paper to account No. 50-0710 (Order No.: JCLA21671)

RESPONSE TO RESTRICTION REQUIREMENT

MAIL STOP Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir,

In response to the Requirement of January 15, 2010, Applicants have elected Group I including claims 1-20, 37-48,50-57 and elected a Species being blood coagulation factor 13 on which claims 1-4, 6-20, 37-39, 42-43, 45-48, 50 are readable, withdrawn the claims of the non-elected Groups and Species, and amended/canceled claims 1-2 & 10-11/6-7. Nevertheless, Applicants submit that two more Species should be elected from claims 40-41, 44 and claim 51-57 respectively as the modifications in claims 40-41, 44, the agents/ effects in claims 51-57 and the thrombin substrates in claims 4-5 are clearly in different categories, and would like to further elect carbodiimide from claims 40-41 & 44 and elect the antithrombotic agent from claim 51-57. Please enter the following amendments.